Formulation and Evaluation of Liquisolid Compacts of Diclofenac Sodium

References

1. 1.↵
   1. Javadzadeh Y.,
   2. Navimipour B.,
   3. Nokhodchi A.

   Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine). Int. J. Pharm. 2007, 341 (1–2), 26–34.

   OpenUrlPubMed
2. 2.↵
   1. Spireas S.,
   2. Sadu S.,
   3. Grover R.

   In vitro release evaluation of hydrocortisone liquisolid tablets. J. Pharm. Sci. 1998, 87 (7), 867–872.

   OpenUrlPubMed
3. 3.↵
   1. Nokhodchi A.,
   2. Javadzadeh Y.,
   3. Siahi Shadbad M. R.,
   4. Barzegar-Jalali M.

   The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts. J. Pharm. Pharm. Sci. 2005, 8 (1), 18–25.

   OpenUrlPubMed
4. 4.↵
   1. Darwish A. M.,
   2. El-Kamel A. H.

   Dissolution enhancement of glibenclamide using liquisolid tablet technology. Acta Pharm. 2001, 51 (3), 173–218.

   OpenUrl
5. 5.↵
   1. Rathbone M. J.,
   2. Hadgraftb J.,
   3. Roberts M. S.

   1. Charman S. A.,
   2. Charman W. N.

   Oral modified release delivery systems. In Rathbone M. J., Hadgraftb J., Roberts M. S. Modified Release Drug Delivery Technology; Marcel Dekker, Inc.: New York, 2003; pp 1–9.
6. 6.
   1. Shinde A. J.

   Solubilization of Poorly Soluble Drugs: A Review. http://www.pharmainfo.net/reviews/solubilization-poorly-soluble-drugs-review.
7. 7.↵
   1. Spiras S.,
   2. Bolton S. M.

   Liquisolid Systems and Methods for Preparing Same. U.S. Patent 6,423,339, B1, 2002.
8. 8.↵
   1. Spiras S.

   ; Liquisolid Systems and Methods for Preparing Same. U.S. Patent 6,096,337, 2000.
9. 9.↵
   1. Spiras S.,
   2. Bolton S. M.

   Liquisolid Systems and Methods for Preparing Same. U.S. Patent 5,968,550, 1999.
10. 10.↵
    1. Javadzadeh Y.,
    2. Siahi M. R.,
    3. Asnaashri S.,
    4. Nokhodchi A.

    An investigation of physicochemical properties of piroxicam liquisolid compacts. Pharm. Dev. Technol. 2007, 12 (3), 337–343.

    OpenUrlPubMed
11. 11.↵
    1. Javadzadeh Y.,
    2. Siahi-Shadbad M. R.,
    3. Barzegar-Jalali M.,
    4. Nokhodchi A.

    Enhancement of dissolution rate of piroxicam using liquisolid compacts. Farmaco 2005, 60 (4), 361–365.

    OpenUrlPubMed
12. 12.↵
    1. Sweetman S. C.

    ; Martindale: The Complete Drug Reference, 33rd ed.; The Pharmaceutical Press: London, 2002; pp 30–31.
13. 13.↵
    1. Dollery C.

    ; Therapeutic Drugs; Churchill Livingstone: Edinburgh, 1999; pp D88–89.
14. 14.↵
    1. Tripathi K. D.

    ; Essentials of Medical Pharmacology, 5th ed.; Jaypee Brothers Medical Publications: New Delhi, India, 2003; pp 184–201.
15. 15.↵
    1. Bertocchi P.,
    2. Antoniella E.,
    3. Valvo L.,
    4. Alimonti S.,
    5. Memoli A.

    Diclofenac sodium multisource prolonged release tablets—a comparative study on the dissolution profiles. J. Pharm. Biomed. Anal. 2005, 37 (4), 679–685.

    OpenUrlPubMed
16. 16.↵
    1. Spiras S.,
    2. Wang T.,
    3. Grover R.

    Effect of powder substrate on dissolution properties of methyclothiazide liquisolid compacts. Drug. Dev. Ind. Pharm. 1999, 25 (2), 163–168.

    OpenUrlPubMed
17. 17.↵
    1. Fahmy R. H.,
    2. Kassem M. A.

    Enhancement of famotidine dissolution rate through liquisolid tablet formulation: in vitro and in vivo evaluation. Eur. J. Pharm. Biopharm. 2008, 69 (3), 993–1003.

    OpenUrlPubMed
18. 18.↵
    1. Tayel S. A.,
    2. Soliman I.,
    3. Louis D.

    Improvement of dissolution properties of carbamazepine through application of the liquisolid tablet technique. Eur. J. Pharm. Biopharm. 2008, 69 (1), 342–347.

    OpenUrlPubMed
19. 19.
    1. Spireas S.,
    2. Jarowski C. I.,
    3. Rohera B. D.

    Powdered solution technology: principles and mechanism. Pharm. Res. 1992, 9 (10), 1351–1358.

    OpenUrlPubMed
20. 20.
    1. Rowe R. C.,
    2. Sheskey P. J.,
    3. Weller P. J.

    ; Handbook of Pharmaceutical Excipients, 4th ed.; American Pharmaceutical Association: Chicago, 2003; pp 108–111, 361, 407–466.
21. 21.↵
    1. Shenoy V.,
    2. Agraval S.,
    3. Pandey S.

    Optimizing fast dissolving dosage form of diclofenac sodium by rapidly disintegrating agents. Ind. J. Pharm. Sci. 2003, 65 (2), 197–200.

    OpenUrl
22. 22.↵
    1. Spireas S.,
    2. Sadu S.

    Enhancement of prednisolone dissolution properties using liquisolid compacts. Int. J. Pharm. 1998, 166 (2), 177–188.

    OpenUrl
23. 23.↵
    1. Staniforth J.

    ; Powder Flow. In Pharmaceutics: The Science of Dosage Form Design, 2nd ed.; Churchill Livingstone: Edinburgh, 2002; pp 114–138.
24. 24.↵
    1. Wells J.

    Pharmaceutical Preformulation: The Physicochemical Properties of Drug Substances. In Pharmaceutics: The Science of Dosage Form Design, 2nd ed.; Churchill Livingstone: Edinburgh, 2002; pp 114–138.
25. 25.↵
    United States Pharmacopoeia 24; US Pharmacopoeial Convention: Rockville, MD, 1993; pp 546–547, 2148–2149.
26. 26.↵
    1. Banker G. S.,
    2. Anderson N. R.

    Tablets. In The Theory and Practice of Industrial Pharmacy, 3rd ed.; Varghese Publishing House: Bombay, India, 1991; pp 293–345.
27. 27.↵
    Indian Pharmacopoeia, Gov. of India, Ministry of Health and Family Welfare, Delhi; Controller of India: New Delhi, India, 2007; pp 662–663, 1021–1022.
28. 28.↵
    1. Zilnik L. F.,
    2. Jazbinseka A.,
    3. Hvala A.,
    4. Vrecerb F.

    Solubility of diclofenac sodium in different solvents. http://ppeppd07.chemeng.ntua.gr/manuscripts/298.pdf.
29. 29.↵
    1. Brittain H. G.

    1. Amidon G. E.

    Physical and Mechanical Property Characterization of Powders. Brittain H. G. Physical Characterization of Pharmaceutical Solids, Drugs and Pharmaceutical Sciences; Marcel Dekker, Inc.: New York 1995; Vol. 70; pp 282–317.

    OpenUrl